RxDoctor Payments Data

Essam Almeky, MD

Family Medicine · Shavertown, PANPI 1548442684

Payments from drug & device makers

$13,126in general payments, 2019–2025

Across 677 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$870
  • Amgen$845
  • GSK$805
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$13,04299%
  • Education$841%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,126 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$245,865
Medicare patients
448
Services billed
3,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide250$315,161
EliquisApixaban296$176,522
FarxigaDapagliflozin Propanediol177$131,163
JardianceEmpagliflozin79$51,718
JanuviaSitagliptin Phosphate58$50,718
WegovySemaglutide32$43,860
MounjaroTirzepatide33$36,387
TrulicityDulaglutide26$33,552
XareltoRivaroxaban51$29,250
RybelsusSemaglutide12$29,015
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$24,818
SantylCollagenase Clostridium Hist.29$23,441
MyrbetriqMirabegron23$15,694
NuedextaDextromethorphan Hbr/Quinidine19$13,868
EntrestoSacubitril/Valsartan18$9,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$2,875$388,037294 claims
PfizerEliquis$378$176,522296 claims
AstraZenecaFarxiga$1,187$131,163177 claims
Lilly USA, LLCMounjaro, Trulicity$870$69,93959 claims
Boehringer IngelheimJardiance$581$51,71879 claims
MerckJanuvia$42$50,71858 claims
GSKTrelegy Ellipta, Breo Ellipta$805$33,34057 claims
Johnson & JohnsonXarelto$58$29,25051 claims
Astellas Pharma US IncMyrbetriq$292$15,69423 claims
Avanir Pharmaceuticals, Inc.Nuedexta$12$13,86819 claims
NovartisEntresto$105$9,90618 claims
AbbVieLinzess$1,907$5,59311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Shavertown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →